Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05245500
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRTX1719 — DRUG
    MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days

Study Details

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Key Dates

Start date
Jun 9, 2022
Status verified
Dec 2025
Primary completion
Dec 10, 2027
Completion
Dec 10, 2027

Study Design

Enrollment
336 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1/1B
    Dose Escalation/Evaluation
  • Experimental: Phase 1b Sub-studies 1-4
  • Experimental: Phase 1b Sub-study 5

Primary Outcome Measure

Number of Patients who Experience Dose-Limiting Toxicity [ Time Frame: 21 days ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain the NCT# and Site #.

Locations (25)

FacilityCityStateZIPSite coordinators
Mayo ClinicPhoenixArizona85054-4502
Tanios Bekaii-Saab, Site 113
480-301-8000
Sarah Cannon Research Institute (SCRI) - HealthONE LocationDenverColorado80218-1238
Sreenivasa Chandana, Site 106
269-993-6056
Rocky Mountain Cancer Centers, LLP - OncologyLone TreeColorado80124
Robert Jotte, Site 109
303-430-2700
Mayo ClinicJacksonvilleFlorida32224
Hani Babiker, Site 114
000000000
Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlandoFlorida32827
Cesar Perez Batista, Site 121
Local Institution - 124ChicagoIllinois60637-
Dana-Farber Cancer InstituteBrooklineMassachusetts02251
Pasi Janne, Site 103
617-632-6036
Cancer and Hematology Centers of Western MichiganNorton ShoresMichigan49444
Sreenivasa Chandana, Site 131
269-993-6056
Mayo ClinicRochesterMinnesota55905
Lei Deng, Site 112
206-606-4801
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08901
Kristen Spencer, Site 127
732-235-2465
Local Institution - 129MineolaNew York11501
Site 129
David H Koch, Memorial Sloan Kettering Cancer CenterNew YorkNew York10021
Kathryn Arbour, Site 104
646-608-3792
New york cancer and blood specialists - OncologyPort Jefferson StationNew York11776
Richard Zuniga, Site 101
631751050
New york cancer and blood specialists - OncologyPort Jefferson StationNew York11776
Richard Zuniga, Site 115
University of North CarolinaChapel HillNorth Carolina27599
Shetal Patel, Site 125
University of North Carolina - Gastroenterology and HepatologyChapel HillNorth Carolina27599
Shetal Patel, Site 107
Vanderbilt - Ingram Cancer CenterNashvilleTennessee37232-5505
Elizabeth Davis, Site 132
206-341-1111
Ut SouthwesternDallasTexas75235
Salwan Al Mutar, Site 120
Texas Oncology - DFWFort WorthTexas76104
Andrew Paulson, Site 111
214-370-1000
MDACCHoustonTexas77030
Jordi Ahnert, Site 105
South Texas Accelerated Research TherapeuticsSan AntonioTexas78229
Kyriakos Papadopoulos, Site 102
Texas Oncology, P.A. - OncologyTylerTexas78503
Donald Richards, Site 110
903-579-9800
Virginia Cancer Specialists, PCFairfaxVirginia22031
Alexander Spira, Site 122
703-280-5390
Local Institution - 134SeattleWashington98109-
Local Institution - 108MilwaukeeWisconsin53226-

Find similar trials in Phoenix, AZ

By condition
Lung cancerPancreatic cancer
By specialty
OncologyLung oncologyLung diseaseGI oncology
By research site
Mayo Clinic· Phoenix, AZSarah Cannon Research Institute (SCRI) - HealthONE Location· Denver, CORocky Mountain Cancer Centers, LLP - Oncology· Lone Tree, COMayo Clinic· Jacksonville, FLSarah Cannon Research Institute at Florida Cancer Specialists· Orlando, FLLocal Institution - 124· Chicago, IL

Related Studies